Oruka Therapeutics (NASDAQ:ORKA) Upgraded by BTIG Research to “Strong-Buy” Rating

Oruka Therapeutics (NASDAQ:ORKA) was upgraded by equities researchers at BTIG Research to a “strong-buy” rating in a research report issued on Thursday, MarketBeat.com reports. The brokerage currently has a $44.00 target price on the stock. BTIG Research’s target price suggests a potential upside of 293.21% from the company’s current price.

ORKA has been the subject of a number of other reports. Wedbush reaffirmed an “outperform” rating and issued a $40.00 target price on shares of Oruka Therapeutics in a report on Thursday, May 15th. Wolfe Research assumed coverage on Oruka Therapeutics in a report on Tuesday, February 4th. They set an “outperform” rating and a $20.00 price objective for the company. Finally, HC Wainwright reissued a “buy” rating and issued a $45.00 target price on shares of Oruka Therapeutics in a report on Friday, February 7th. One investment analyst has rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $40.38.

Oruka Therapeutics Trading Up 5.8%

Shares of ORKA opened at $11.19 on Thursday. The stock’s 50 day moving average is $9.80 and its two-hundred day moving average is $14.40. Oruka Therapeutics has a twelve month low of $5.49 and a twelve month high of $31.13. The firm has a market capitalization of $418.96 million, a PE ratio of -1.79 and a beta of 0.25.

Oruka Therapeutics (NASDAQ:ORKA) last announced its quarterly earnings data on Wednesday, May 14th. The company reported ($0.40) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.17. On average, sell-side analysts predict that Oruka Therapeutics will post -3.41 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. China Universal Asset Management Co. Ltd. purchased a new stake in Oruka Therapeutics in the fourth quarter valued at approximately $144,000. AlphaCentric Advisors LLC acquired a new stake in Oruka Therapeutics in the 4th quarter valued at $119,000. Charles Schwab Investment Management Inc. acquired a new stake in Oruka Therapeutics in the 4th quarter valued at $303,000. Vanguard Group Inc. raised its position in Oruka Therapeutics by 4,161.2% in the fourth quarter. Vanguard Group Inc. now owns 1,610,651 shares of the company’s stock valued at $31,231,000 after purchasing an additional 1,572,853 shares during the period. Finally, JPMorgan Chase & Co. acquired a new position in shares of Oruka Therapeutics during the fourth quarter worth about $54,000. Hedge funds and other institutional investors own 56.44% of the company’s stock.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.